Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ROMANCE GOIM Study: A Phase II, Open Label, Multicenter Trial Investigating Irinotecan Plus Cetuximab Rechallenge Compared With Trifluridine/Tipiracil Plus Bevacizumab as Third Line Treatment in Circulating Tumor DNA Molecularly Selected Metastatic Colorectal Cancer

NCT07381764 is registered in ClinicalTrials.gov with Gruppo Oncologico Italia Meridionale as lead sponsor.

NCT NCT07381764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07381764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ROMANCE GOIM Study: A Phase II, Open Label, Multicenter Trial Investigating Irinotecan Plus Cetuximab Rechallenge Compared With Trifluridine/Tipiracil Plus Bevacizumab as Third Line Treatment in Circulating Tumor DNA Molecularly Selected Metastatic Colorectal Cancer
Lead sponsor
Gruppo Oncologico Italia Meridionale
Phase
Phase 2
Overall status
Recruiting
Start date
March 20, 2026
Completion date
March 30, 2031
Enrollment
150 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc)